GSK Gsk Plc

TIDMGSK

RNS Number : 1926Z

GlaxoSmithKline PLC

08 January 2020

Issued: 8 January 2020, London UK

Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Deborah Waterhouse, CEO of global specialist HIV company ViiV Healthcare, will join GSK's Corporate Executive Team (CET) with immediate effect. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders.

Deborah joined GSK in 1996 and has worked in a number of commercial leadership roles in Europe, Asia-Pacific and the USA. She has a strong track record of performance in both specialty and primary care medicines and brings further commercial focus to the CET.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

 
 GSK enquiries: 
 UK Media enquiries:   Simon Steel          +44 (0) 20 8047   (London) 
                                             5502 
                       Mary Hinks-Edwards   +44 (0) 20 8047   (London) 
                                             5502 
 
 
 Analyst/Investor      Sarah Elton-Farr     +44 (0) 208       (London) 
  enquiries:                                 047 5194 
                       Danielle Smith       +44 (0) 20 8047   (London) 
                                             7562 
                       James Dodwell        +44 (0) 20 8047   (London) 
                                             2406 
 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEALFPEDDEEFA

(END) Dow Jones Newswires

January 08, 2020 09:37 ET (14:37 GMT)

Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024